C2 Micro Inc.
KeenHigh Technologies Ltd.
Vtion Wireless Technologies
JinkoSolar Holding Co., Ltd.
LuHua Chemical Co.
Celgen Biopharmaceutical co, Ltd
China Dredging
Juli
Huiji
Pingtan Marine Enterprise LTD
Celgen Biopharmaceutical co, Ltd

 

 

 

 

Shanghai Celgen Biopharmaceutical co, Ltd ("Celgen"), is a leading bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgenís main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgenís Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

China Israel Value Capital (CIVC) and Shenzhen Capital Group Co., (SCGC) invested in the company in July 2009.